Arvinas FY2027 EPS Estimate Decreased by Leerink Partnrs

Arvinas, Inc. (NASDAQ:ARVN) – Investment analysts at Leerink Partnrs dropped their FY2027 earnings per share (EPS) estimates for shares of Arvinas in a report released on Monday, February 3rd. Leerink Partnrs analyst A. Berens now anticipates that the company will post earnings per share of $1.08 for the year, down from their previous estimate of $1.38. The consensus estimate for Arvinas’ current full-year earnings is ($3.22) per share.

Other equities research analysts have also recently issued reports about the stock. Barclays reduced their target price on shares of Arvinas from $48.00 to $32.00 and set an “overweight” rating for the company in a research report on Monday. Stephens initiated coverage on shares of Arvinas in a research report on Monday, November 18th. They set an “overweight” rating and a $55.00 price objective for the company. BTIG Research assumed coverage on shares of Arvinas in a research note on Tuesday, December 10th. They issued a “buy” rating and a $69.00 price objective for the company. Guggenheim restated a “buy” rating on shares of Arvinas in a report on Thursday, December 12th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $87.00 price objective on shares of Arvinas in a research report on Wednesday, December 11th. One analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $61.45.

Arvinas Price Performance

Arvinas stock opened at $19.59 on Thursday. The stock has a market capitalization of $1.35 billion, a PE ratio of -4.19 and a beta of 1.88. Arvinas has a 12 month low of $16.61 and a 12 month high of $53.08. The business has a 50 day simple moving average of $19.89 and a 200-day simple moving average of $23.70.

Institutional Investors Weigh In On Arvinas

A number of large investors have recently made changes to their positions in ARVN. Mirae Asset Global Investments Co. Ltd. raised its stake in Arvinas by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,483 shares of the company’s stock valued at $61,000 after purchasing an additional 440 shares during the period. Rhumbline Advisers raised its position in Arvinas by 0.9% during the fourth quarter. Rhumbline Advisers now owns 87,877 shares of the company’s stock valued at $1,685,000 after buying an additional 754 shares during the period. Assenagon Asset Management S.A. lifted its stake in Arvinas by 0.6% in the 4th quarter. Assenagon Asset Management S.A. now owns 140,518 shares of the company’s stock worth $2,694,000 after acquiring an additional 777 shares in the last quarter. KBC Group NV boosted its position in Arvinas by 77.0% during the 4th quarter. KBC Group NV now owns 2,885 shares of the company’s stock worth $55,000 after acquiring an additional 1,255 shares during the period. Finally, China Universal Asset Management Co. Ltd. grew its stake in Arvinas by 10.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 14,570 shares of the company’s stock valued at $279,000 after acquiring an additional 1,367 shares in the last quarter. Institutional investors and hedge funds own 95.19% of the company’s stock.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.